 "MSN Labs enters into licence deal with DRDE for Covid-19 drug 2-DG")
Drug firm MSN Laboratories on Friday said it has entered into a licence agreement with the Defence Research & Development Establishment (DRDE) for the manufacturing, distribution and marketing of 2-Deoxy-D-Glucose (2-DG), used for the treatment of COVID-19.
Developed by DRDO, 2-DG has been granted permission by the Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, MSN Labs said in a statement.
The company has entered into a licence agreement with DRDE and the Institute of Nuclear Medicine and Allied Sciences (INMAS) establishments of DRDO for the manufacturing, distribution and marketing of 2-Deoxy-D-Glucose (2-DG) in India, it added.
MSN labs will be launching the 2-DG as a twice-a-day product in sachet form under the brand name MSN 2D in strength of 2.34 g, the statement said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
